Project Sponsor, MD, PhD, MCU-PH, Team Leader, PI, Sorbonne Université, AP-HP
Project Sponsor, MD, PhD, MCU-PH, Team Leader, PI, Sorbonne Université, AP-HP
Team presentation
Investigating brain tumor evolution, mechanisms of resistance to chemotherapy, development of therapeutic strategies to overcome this resistance, and interactions between brain tumors and immune system.
The team is also working with Gliotex, the glioblastoma drug review service.
- Touat M et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 Apr;580(7804):517-523.
- Di Stefano AL et al. Clinical, Molecular and Radiomic Profile of Gliomas With FGFR3-TACC3 Fusions. Neuro Oncol 2020 May 15:noaa121. doi: 10.1093/neuonc/noaa121.
- D’Angelo F et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019 Jan;25(1):176-187.
- Idbaih A et al. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2019 Jul 1;25(13):3793-3801.
- Rosenberg S et al. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Nat Commun. 2018 Jun 18;9(1):2371
- Labreche K et al. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathol. 2018 May;135(5):743-755.
- Frattini V et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature. 2018 Jan 11;553(7687):222-227
Team members
Project Sponsor, MD, PhD, MCU-PH, Team Leader, PI, Sorbonne Université, AP-HP
Project Sponsor, MD, PhD, MCU-PH, Team Leader, PI, Sorbonne Université, AP-HP
Clinician, MD, PhD, PH, PI, AP-HP
Research Officer (CRCN), PI, INSERM
Clinician, MD, PhD, PU-PH, PI, Sorbonne Université, AP-HP
Project Sponsor, MD, PhD, MCU-PH, PI, Sorbonne Université, AP-HP
Project Sponsor, PhD, CRCN, PI, INSERM
Director of Research, PI, INSERM
MD, PhD, Pr (PU-PH), PI, Sorbonne Université, AP-HP
